Status:
RECRUITING
Improving Survival of COlorectal LIver Metastases by RFA-mediated Immunostimulation
Lead Sponsor:
University of Aarhus
Collaborating Sponsors:
Aarhus University Hospital
Rigshospitalet, Denmark
Conditions:
Liver Metastasis Colon Cancer
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
To examine radio frequency ablation as a treatment supplement to stimulate immunogenicity and improve survival for patients undergoing curative-intent surgery for colorectal liver metastases.
Detailed Description
PURPOSE: To investigate the impact of immunostimulation using radio frequency ablation (RFA) on survival in patients undergoing curative-intent surgery for colorectal liver metastases (CRLM). HYPOTH...
Eligibility Criteria
Inclusion
- Patients with colorectal liver metastases planned for resection
- At least one tumor size \>=3cm
- Performance status 0-1
Exclusion
- Liver cirrhosis
- Extrahepatic metastases that can not be addressed curatively
- Other malignant diseases within 5 years prior to diagnosis
- Prior RFA treatment
Key Trial Info
Start Date :
November 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04798898
Start Date
November 14 2022
End Date
December 1 2026
Last Update
December 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital, Department of Surgery
Aarhus, Denmark, 8200